Eggertsen R, Hansson L
Eur J Clin Pharmacol. 1982;21(5):389-90. doi: 10.1007/BF00542324.
In a double-blind trial 26 patients with essential hypertension were treated with nifedipine or placebo for 8 weeks, following a 4-week run-in-placebo period in all patients. The daily dosage of nifedipine during this phase was 10 mg 3 times daily. Metoprolol was then added to the therapeutic regimen of both groups for a further 12 weeks. Both nifedipine and metoprolol used as mono-therapy caused statistically significant reductions of arterial pressure. The addition of metoprolol to nifedipine tended to reduce blood pressure further, but blood pressures were not significantly lower than during nifedipine mono-therapy. Side-effects were few and only two patients had to be withdrawn during active therapy, one for headaches during nifedipine therapy, and another for asthma during metoprolol treatment. Combined therapy with a beta-adrenoceptor blocking agent, such as metoprolol, and a calcium antagonist with vasodilation properties, such as nifedipine, offers a theoretically interesting approach in the treatment of hypertension, even though the practical outcome in the present study probably suffered from an inadequate dose of nifedipine during the period of combined therapy.
在一项双盲试验中，26例原发性高血压患者在全部患者经过4周的安慰剂导入期后，接受硝苯地平或安慰剂治疗8周。在此阶段，硝苯地平的每日剂量为10毫克，每日3次。然后两组的治疗方案中均加用美托洛尔，持续12周。硝苯地平和美托洛尔单药治疗均使动脉压出现具有统计学意义的下降。硝苯地平加用美托洛尔有使血压进一步降低的趋势，但血压并不显著低于硝苯地平单药治疗时。副作用较少，在积极治疗期间只有2例患者退出，1例在硝苯地平治疗期间因头痛退出，另1例在美托洛尔治疗期间因哮喘退出。联合使用β肾上腺素受体阻滞剂（如美托洛尔）和具有血管舒张特性的钙拮抗剂（如硝苯地平）在高血压治疗中提供了一种理论上有意义的方法，尽管本研究的实际结果可能受到联合治疗期间硝苯地平剂量不足的影响。
